Switzerland· 66696002
Cerdelga
A eliglustat product containing eliglustatum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Eliglustat is registered in 17 of 19 countries.
Countries holding a registration under ATC A16AX10 (eliglustat), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 11 of them publish a price we can compare per daily dose
Eliglustat · ATC A16AX10
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of eliglustat costs, country by country.
Normalised to the WHO defined daily dose (0.168 g), so markets compare like for like.
- Switzerland: $1116.28 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Eliglustat · price per daily dose (0.168 g)
USD · FX 28 Sept 2026
- CH Switzerland$1116.28
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- eliglustatum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- A16AX10
- ATC class
- Eliglustat
- Defined daily dose
- 0.168 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680666960028Blist 56 StkCHF 26044.7
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
336 interactions on record for eliglustat.
Graded by severity as the source publishes them — 119 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eliglustat · interactions on record
336 records
- 119 severe
- 210 moderate
- 7 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- CimetidineA02BA01severe
- DiphenhydraminA04AB05severe
- AprepitantA04AD12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Eliglustat in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCERDELGASanofi B.V., Amsterdam
- SpainCERDELGA 84 MG CAPSULAS DURASSanofi B.V.
- FinlandCerdelgaSanofi B.V.
- FranceCERDELGA 84 mg, géluleSANOFI (PAYS-BAS)
- IrelandCerdelga 84mg Hard capsuleSanofi B.V.
- IcelandCerdelgaSanofi B.V.
- NetherlandsCerdelga 84 mg, capsule, hardGenzyme Europe BV
- NorwayCerdelgaSanofi B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cerdelga
- Liechtenstein · Cerdelga
- Norway · Cerdelga
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5fac6ca7-f201-4897-a314-9aa5ab0bceb5 GET /v1/drugs/5fac6ca7-f201-4897-a314-9aa5ab0bceb5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "eliglustatum 84.4 mg",
"valid_from": "2022-06-01",
"limitations": "[{\"description\":\"Zur Monotherapie bei erwachsenen Patienten ab 18 Jahren mit gesicherter Diagnose eines Morbus Gaucher Typ I, die in Bezug auf Cytochrom-P450 Typ2D6 (CYP2D6) langsame Metabolisierer (poor metabolizers, PMs), intermediäre Metabolisierer (intermediate metabolizers, lMs) oder schnelle Metabolisierer (extensive metabolizers, EMs) sind. Kein Einsatz bei ultraschnellen Metabolisierern oder unklarem Metabolisierungsstatus in Bezug auf Cytochrom-P450 Typ 2D6 (CYP2D6).<br> \\nDie Bestimmung des CYP2D6-Metabolisierungsstatus muss vor der Therapie mit einer validierten Testmethode erfolgen. Die Kosten für den Test werden von sanofi-aventis (suisse) sa übernommen.<br> \\nDie Erstverordnung darf nur durch ein auf hereditäre Stoffwechselerkrankungen spezialisiertes Zentrum oder einen Facharzt/eine Fachärztin mit Erfahrung auf dem Gebiet von hereditären Stoffwechselerkrankungen erfolgen. Alle sechs Monate ist eine Kontrolluntersuchung durch das o.a. Zentrum oder den/die o. a Facharzt/Fachärztin durchzuführen.<br> \\nCERDELGA darf nicht mit anderen für die Indikation Morbus Gaucher zugelassenen Medikamente kombiniert werden.<br> \\nDer behandelnde Arzt ist verpflichtet Patienten auf Cerdelga Behandlung laufend im International Collaborative Gaucher Group (ICGG) Registry (clinicaltrials.gov NCT00358943) (https://www.registrynxt.com/) zu erfassen. Sofern ein Patient keine Einwilligung zur Erfassung seiner Daten in das Register gibt, muss dies ausgewiesen werden.<br> \\n<br>\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2022-06-01\",\"validTo\":null}]",
"galenic_form": "Kaps 84 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2022-06-01",
"self_retention_pct": 10
}See everything about eliglustat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.